HealthTech Bioactives and Abolis Biotechnologies partner to develop solvent-free, fermentation-based production methods for polyphenols

Image courtesy of HTBA

HealthTech Bioactive (HTBA; Barcelona, Spain), an innovator of polyphenol and vitamin B12 solutions for both human and animal health and nutrition applications, has announced a partnership with France-based Abolis Biotechnologies for the production of sustainable polyphenols. Abolis Biotechnologies specializes in microbial strain development and biotechnological production methods.

HealthTech Bioactives explains in a press release that initially, the partnership will focus on the development of two high-value molecules that are currently experiencing limited sourcing availability. After the completion of this initial phase, the established protocols will be applied to eight additional molecules. Overall, the goal is to increase and secure polyphenol manufacturing capacities and reduce costs compared to traditional extraction methods.

“Our companies have been working successfully together since 2021 and we are still amazed by the Abolis team, whose values align with our own,” said Alexandre Valls-Coma, CEO of HTBA, in a press release. “We are delighted to announce this new phase of our partnership and truly believe that it will take polyphenols to the next level and create to more value for our customers.”

“We are thrilled to contribute to HTBA’s growth through this strategic collaboration," added Cyrille Pauthenier, co-founder and CEO of Abolis. "Abolis has a proven track record in microbial strain development for polyphenol products, while HTBA brings its extensive global market knowledge to identify innovative applications for our solutions. This partnership is therefore a perfect match for our complementary expertise.”